Artikel
Efficacy and safety data from real life treatment of first in Germany registered intravesical oxybutynin for patients with neurogenic detrusor overactivity (NDO)
Suche in Medline nach
Autoren
-
Yorck-Bernhard Kalke
- Spinal cord injury center of the Orthopaedic University Hospital Ulm, Ulm, Germany
-
Huyen-Tran Ho
- FARCO-PHARMA GmbH, Cologne, Germany
-
Quentin Leidl
- FARCO-PHARMA GmbH, Cologne, Germany
-
Almuth Angermund
- Centre for Neuro-Urology, Schön Klinik Vogtareuth, Vogtareuth, Germany
-
Ronen Elishar
- Klinikum Bayreuth GmbH, Bayreuth, Germany
-
Martina Frech-Dörfler
- Universitäts-Kinderspital beider, Basel, Switzerland
-
Almut Hirsch
- Cnopfsche Kinderklinik, Nürnberg, Germany
-
Ruth Kirschner-Hermanns
- Johanniter Rehabilitationszentrum Godeshöhe, Bonn-Godesberg, Germany
-
Jure Tornic
- Department of Urology, Kantonsspital Wintherthur, Winterthur, Switzerland
-
Fabian Queissert
- Department of Urology and Children’s Urology, University Hospital Münster, Münster, Germany
-
Sajad Rahnama'i
- Urology Tweesteden hospital, Tilburg, Netherlands
-
Christian Rehme
- Department of Urology, University Hospital Essen, Essen, Germany
-
Andrè Reitz
- Kontinenz Zentrum AG, Klinik Hirslanden, Zürich, Switzerland
-
Oliver Schindler
- Department of Urology and Children’s Urology, University Hospital Ulm, Ulm, Germany
-
Franziska Schmitz
- Neuro-Urologie/Urologie und Kinderurologie, Universitätsklinikum Bonn, Bonn, Germany
-
Daniela Schultz-Lampel
- Continence Center Southwest, Schwarzwald-Baar Klinikum, Villingen-Schwenningen, Germany
-
Michael Gedamke
- FARCO-PHARMA GmbH, Cologne, Germany
| Veröffentlicht: | 31. Oktober 2023 |
|---|
Gliederung
Text
Introduction: Existing therapies for NDO, i.e. oral anticholinergics and botulinum toxin injections, can have severe adverse effects or are not always sufficiently effective. Therefore, there is a need for alternative safe and efficient treatment methods for NDO patients. To date, limited efficacy, and safety data for the newly registered intravesical oxybutynin therapy in NDO patients are present.
Methods: 38 medical reports from 14 physicians in Germany, Netherlands, and Switzerland were collected in the context of daily treatment routine of NDO patients. Data from examinations before and during the intravesical oxybutynin VESOXX® treatment were analyzed for different patient groups.
Results: In spinal cord injury, spina bifida, and several other patients with NDO causing etiology, the change in therapy to intravesical oxybutynin or a co-therapy with intravesical oxybutynin in the pooled data set significantly reduced detrusor pressure from 51.94 cmH2O ± 4.48 SEM to 22.54 cmH2O ± 3.56 SEM (n=34) and increased maximum bladder capacity from 260.45 ml ± 34.86 SEM to 348.45 ml ± 30.62 SEM (n=33). Similar or positive effects in comparison to prior therapies used, could be seen in bladder morphology, incontinence frequencies, urinary tract infections, and adverse drug effects.
Conclusion: Overall, the case series shows that intravesical oxybutynin is an important addition to current therapies for the treatment of NDO. The registered intravesical oxybutynin drug VESOXX® can be a useful alternative for patients who are refractory to other therapy methods or for vulnerable patients like infants.
Conflicts of interest:
- Ho, Leidl, Gedamke: Employees of FARCO-Pharma GmbH
- Dr. Angermund: Consultant fee
- Dr. Hirsch: Consultant fee
- Prof. Kirschner-Hermanns: Lecture fee
- Dr. Queissert: Lecture fee
- Dr. Rahnama'i: Consultant fee
- Prof. Reitz: Consultant fee
